Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 4/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.39 |
| ▸ | MAOA | P21397 | 2/20 | 0.39 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | GSR | P00390 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | CES1 | P23141 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14940557 | 0.84 | CA12 (0.40) | CA12CA9NOTUMKDM4EALDH1A1 | |
| SCHEMBL7391653 | 0.73 | KEAP1 (0.43) | CA12CA9NOTUMKDM4EALDH1A1 | |
| SCHEMBL31147237 | 0.72 | SRD5A2 (0.43) | NOTUMKDM4EALDH1A1HPGDLMNA | |
| SCHEMBL335207 | 0.72 | SRD5A2 (0.43) | NOTUMKDM4EALDH1A1HPGDLMNA | |
| SCHEMBL7385627 | 0.70 | EGFR (0.35) | CA12CA9NOTUMKDM4EALDH1A1 | |
| SCHEMBL8119477 | 0.69 | SRD5A2 (0.49) | NOTUMKDM4EALDH1A1HPGDLMNA | |
| SCHEMBL3373516 | 0.69 | CA12 (0.53) | CA12CA9NOTUMKDM4EALDH1A1 | |
| SCHEMBL16247863 | 0.68 | CA12 (0.42) | CA12CA9ALDH1A1MAOAPARP1 | |
| SCHEMBL24202154 | 0.68 | CA12 (0.38) | CA12CA9LMNASMN1; SMN2MAPT | |
| SCHEMBL6173202 | 0.68 | CA12 (0.42) | CA12CA9KDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023165591-A1 | COMPOUNDS AND THEIR USES AS LPAR5 ANTAGONISTS | IMMUTHER PHARMATECH (SHANGHAI) CO., LTD. (CN) | 2023-09-07 | — | — | WO | disclosed |
| EP-3723753-A1 | INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN | Praxis Biotech LLC (US) | 2020-10-21 | — | — | EP | disclosed |
| EP-3694856-A1 | FUSED TRICYCLIC COMPOUNDS AND USES THEREOF IN MEDICINE | Sunshine Lake Pharma Co., Ltd. (CN) | 2020-08-19 | — | — | EP | disclosed |
| WO-2019118932-A1 | INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN | Praxis Biotech LLC (US) | 2019-06-20 | — | — | WO | disclosed |
| WO-2019100735-A1 | FUSED TRICYCLIC COMPOUNDS AND USES THEREOF IN MEDICINE | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2019-05-31 | — | — | WO | disclosed |
| WO-2018219356-A1 | FUSED TRICYCLIC COMPOUNDS AND USES THEREOF IN MEDICINE | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2018-12-06 | — | — | WO | disclosed |
| CN-106459007-A | Pyrimidine-2,4-diamine derivative and anticancer pharmaceutical composition comprising same as effective ingredient | 韩国化学研究院 | 2017-02-22 | — | — | CN | disclosed |
| CN-104203919-A | eterocyclic carboxamides useful as inhibitors of phosphodiesterase type 10A | ABBVIE DEUTSCHLAND | 2014-12-10 | — | — | CN | disclosed |
| CN-101679273-B | 1-substituted tetrahydroisoquinoline compound | ASTELLAS PHARMA INC | 2013-03-06 | — | — | CN | disclosed |
| US-8173639-B2 | Isoquinolinone derivatives as NK3 antagonists | H. LUNDBECK A/S (DK) | 2012-05-08 | — | — | US | disclosed |
| CN-101679273-A | 1-substituted tetrahydroisoquinoline compound | ASTELLAS PHARMA INC | 2010-03-24 | — | — | CN | disclosed |
| EP-2150534-A1 | ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS | H. Lundbeck A/S (DK) | 2010-02-10 | — | — | EP | disclosed |
| US-20090143402-A1 | ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS | H. LUNDBECK A/S (DK) | 2009-06-04 | — | — | US | disclosed |
| WO-2008131779-A1 | ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS | H. LUNDBECK A/S (DK) | 2008-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143402-A1 | ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS | KCNQ3, KCNK3, GRIK3 | CA12 4800/4885CA9 4660/4885NOTUM 4527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.